281 related articles for article (PubMed ID: 35834995)
1. Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes.
Hoshino J; Matsumoto H; Mukai R; Nakamura K; Akiyama H
Ophthalmologica; 2022; 245(5):413-420. PubMed ID: 35834995
[TBL] [Abstract][Full Text] [Related]
2. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
[TBL] [Abstract][Full Text] [Related]
3. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
[TBL] [Abstract][Full Text] [Related]
4. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration.
Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K
Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566
[TBL] [Abstract][Full Text] [Related]
5. Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2021 Mar; 11(1):6759. PubMed ID: 33762600
[TBL] [Abstract][Full Text] [Related]
6. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration.
Sotani R; Matsumiya W; Kim KW; Miki A; Yasuda E; Maeda Y; Hara R; Kusuhara S; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2023 Aug; 261(8):2359-2366. PubMed ID: 36971800
[TBL] [Abstract][Full Text] [Related]
8. Improvements of Retinal Sensitivity after Intravitreal Injection of Aflibercept in Eyes with Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy.
Nizawa T; Kitahashi M; Baba T; Iwase T; Kubota-Taniai M; Hattori Y; Shiko Y; Kawasaki Y; Iwase T; Sato T; Ogawa S; Sugawara T; Yamamoto S
Ophthalmologica; 2021; 244(4):347-360. PubMed ID: 34015785
[TBL] [Abstract][Full Text] [Related]
9. Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Nakamura K; Akiyama H
Sci Rep; 2023 Feb; 13(1):3249. PubMed ID: 36828853
[TBL] [Abstract][Full Text] [Related]
10. Short-term results for brolucizumab in treatment-naïve neovascular age-related macular degeneration: a Japanese multicenter study.
Tanaka K; Koizumi H; Tamashiro T; Itagaki K; Nakayama M; Maruko I; Wakugawa S; Terao N; Onoe H; Wakatsuki Y; Kasai A; Ogasawara M; Shintake H; Sugano Y; Yamamoto A; Kataoka K; Hasegawa T; Izumi T; Kawai M; Maruko R; Sekiryu T; Okada AA; Iida T; Mori R
Jpn J Ophthalmol; 2022 Jul; 66(4):379-385. PubMed ID: 35595951
[TBL] [Abstract][Full Text] [Related]
11. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
[TBL] [Abstract][Full Text] [Related]
12. Using optical coherence tomography angiography in assessment of the anti-vascular endothelial growth factor effect for pathological vascular tissue in age-related macular degeneration and polypoidal choroidal vasculopathy.
Shen YS; Cheng CK
Eur J Ophthalmol; 2021 May; 31(3):1267-1280. PubMed ID: 32228025
[TBL] [Abstract][Full Text] [Related]
13. Short-term outcomes of intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration.
Matsumoto H; Hoshino J; Nakamura K; Nagashima T; Akiyama H
Graefes Arch Clin Exp Ophthalmol; 2023 Oct; 261(10):2945-2952. PubMed ID: 37195339
[TBL] [Abstract][Full Text] [Related]
14. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.
Matsumoto H; Hiroe T; Morimoto M; Mimura K; Ito A; Akiyama H
Jpn J Ophthalmol; 2018 Mar; 62(2):144-150. PubMed ID: 29411171
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal Brolucizumab and Aflibercept for Polypoidal Choroidal Vasculopathy.
Cho HJ; Kang KH; Yoon W; Lee J; Kim CG; Kim JW
J Ocul Pharmacol Ther; 2023 Nov; 39(9):653-660. PubMed ID: 37504966
[No Abstract] [Full Text] [Related]
17. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
18. One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy.
Ito A; Maruyama-Inoue M; Kitajima Y; Ikeda S; Inoue T; Kadonosono K
Sci Rep; 2022 May; 12(1):7987. PubMed ID: 35568780
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.
Inoue M; Yamane S; Sato S; Sakamaki K; Arakawa A; Kadonosono K
Am J Ophthalmol; 2016 Sep; 169():95-103. PubMed ID: 27320059
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
